295 related articles for article (PubMed ID: 24820081)
1. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
Papp-Wallace KM; Winkler ML; Gatta JA; Taracila MA; Chilakala S; Xu Y; Johnson JK; Bonomo RA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4290-7. PubMed ID: 24820081
[TBL] [Abstract][Full Text] [Related]
2. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
3. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
[TBL] [Abstract][Full Text] [Related]
4. High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant.
Shropshire WC; Endres BT; Borjan J; Aitken SL; Bachman WC; McElheny CL; Wu CT; Egge SL; Khan A; Miller WR; Bhatti MM; Saharasbhojane P; Kawai A; Shields RK; Shelburne SA; Doi Y
J Antimicrob Chemother; 2023 Oct; 78(10):2442-2450. PubMed ID: 37574665
[TBL] [Abstract][Full Text] [Related]
5. Avibactam and inhibitor-resistant SHV β-lactamases.
Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185.
Kawai A; Shropshire WC; Suzuki M; Borjan J; Aitken SL; Bachman WC; McElheny CL; Bhatti MM; Shields RK; Shelburne SA; Doi Y
mBio; 2024 Feb; 15(2):e0287423. PubMed ID: 38179965
[TBL] [Abstract][Full Text] [Related]
7. Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam.
Nukaga M; Papp-Wallace KM; Hoshino T; Lefurgy ST; Bethel CR; Barnes MD; Zeiser ET; Johnson JK; Bonomo RA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439972
[TBL] [Abstract][Full Text] [Related]
8. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
10.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
11. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
Winkler ML; Papp-Wallace KM; Bonomo RA
J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
[TBL] [Abstract][Full Text] [Related]
13. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
14. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
15. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
[TBL] [Abstract][Full Text] [Related]
17.
Stone GG; Newell P; Bradford PA
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
[TBL] [Abstract][Full Text] [Related]
18. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
19.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
20. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying
Castanheira M; Mendes RE; Sader HS
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031200
[No Abstract] [Full Text] [Related]
[Next] [New Search]